PALI
Palisade Bio Inc
1.40$
+0.7%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -49.9% | +51.2% | -38.6% | -44.7% | -14.3% | -54.1% | +314.4% | +26.0% | -10.9% | -22.6% | +1,134.8% | |
| – | -52.3% | +55.6% | -40.4% | -47.7% | -13.2% | -84.1% | +1,184.2% | +28.0% | -9.5% | -21.3% | +1,179.0% | |
| – | -62.3% | +222.2% | -56.1% | -13.3% | -11.6% | -86.1% | +1,371.9% | +18.0% | +0.4% | -21.0% | +1,258.2% | |
| – | -55.6% | +65.1% | -42.2% | -50.4% | -11.6% | -85.7% | +1,339.6% | +18.0% | +0.4% | -21.0% | +1,258.2% | |
| – | -83.5% | +70.4% | +484.5% | -3.7% | -94.1% | +180.1% | +154.2% | +858.7% | -89.7% | -83.8% | +1,000.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -35.9% | -97.1% | +8,300.0% | -33.3% | -60.0% | – | – | – | – | |
| – | -10.5% | -10.3% | -10.8% | -13.6% | -12.4% | -78.0% | – | – | – | – | – | |
| – | -17.7% | +12.9% | -52.4% | -69.6% | -10.8% | +594.0% | -49.1% | -36.2% | -16.6% | +23.7% | +46.5% | |
| – | +60.3% | +14.1% | -79.3% | -30.6% | +16.5% | +559.9% | -69.1% | +20.7% | -14.1% | +25.1% | +43.3% | |
| – | +534.9% | -20.0% | – | – | – | +767.9% | -83.6% | -3.0% | +44.6% | -39.4% | -58.0% | |
| – | -41.9% | +61.0% | -62.7% | -4.9% | -1.0% | +207.7% | -40.2% | +15.9% | -60.3% | +73.9% | -36.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -72.0% | +128.1% | -24.8% | -29.0% | -15.3% | -238.5% | – | +69.4% | -9.3% | -33.8% | +1,626.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +5.4% | -92.1% | +2,531.5% | +24.4% | -13.1% | +0.0% | -94.7% | +6,963.3% | -48.2% | +210.5% | +3,831.5% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.